Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Anlotinib with Chemotherapy in Esophageal Cancer
NCT06015035Phase 2Completed
- Sponsor
- Tangdu Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, anlotinib in esophageal cancer, sponsored by Tangdu Hospital. Started Apr 2021; status: completed.
02
Drugs
sintilimabanlotinib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT06015035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015035.